drugset / Trial / NCT00420563

Metronomic Chemotherapy by Cyclophosphamide Versus Megestrol in Palliative Cancer

NCT00420563

Phase 2 Completed 88 enrolled Centre Oscar Lambret
RandomizedParallel-groupOpen-labelTreatment

Summary

The scope of the trial is to assess the free progression rate at 2 months for each group of patients.

Timeline

Start
2009-09-25
Primary completion
2011-01-19
Completion
2011-01-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified 50 mg Oral
Comparator Megestrol Acetate Other / unclassified 320 mg Oral

Indications